Lenvatinib Plus I-125 Seed Brachytherapy vs. Lenvatinib for TACE-refractory HCC

Abroad (travel likely)RecruitingPHASE3

Conditions

Hepatocellular Carcinoma Non-resectable

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

The Second Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong, China
Contact: Study coordinator (Kangshun Zhu, MD) · zhksh010@126.com · +86-20-34156205

View source on ClinicalTrials.gov

Similar trials

Other trials that are currently recruiting and may be relevant based on condition, treatment, phase, or location

Cadonilimab in Combination With Lenvatinib and Hepatic Arterial Infusion Chemotherapy (HAIC) for the Treatment of Unresectable Hepatocellular Carcinoma

Hepatocellular Carcinoma

Abroad (travel likely)RecruitingPHASE2

Changsha, China

Triple Therapy Sequential Radiotherapy in Unresectable HCC (TALENP003)

Hepatocellular Carcinoma Non-resectable

Abroad (travel likely)Recruiting

Fuzhou, China · Fuzhou, China

Study of ADI-PEG 20 Versus Placebo in Subjects With High Arginine Level and Unresectable Hepatocellular Carcinoma

Hepatocellular Carcinoma · Advanced Hepatocellular Carcinoma

Abroad (travel likely)RecruitingPHASE3

Changhua, Taiwan · Chiayi City, Taiwan

Icaritin Soft Capsule Versus Huachansu Tablet in the First-line Treatment of Unresectable Hepatocellular Carcinoma With Poor Conditions and Biomarker Enrichment (Biomarker Enrichment Study of Poor Prognosis HCC Patients, BESTPOP)

Hepatocellular Carcinoma

Abroad (travel likely)RecruitingPHASE3

Nanchang, China · Chifeng, China